Option chain shows key data for NLS Pharmaceutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NLS Pharmaceutics.

NLS Pharmaceutics (NASDAQ:NLSP) Stock, Option Chain

NLS Pharmaceutics

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Medicine

News

Movers

NLSP

NLS Pharmaceutics shares are moving higher on Monday after the company announced it entered into a definitive merger agreement with Kadimastem.

What&#39;s Going On With NLS Pharmaceutics Shares Monday?

movers image

Pre-Market Outlook

Markets

Trading Ideas

ALAR

ATSG

CSWC

EDSA

EFSH

NSSC

NUWE

OKLO

OMIC

SIFY

STAF

TGTX

VSTE

YUMC

Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

AMLI

ATCH

CNTM

CNXC

GSX Techedu Inc. American Depositary Shares

GOTU

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

Kintara Therapeutics, Inc. - Common Stock

KTRA

MDXH

NCNA

SEEL

SONN

SONO

TBIO

VSME

Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket

NLS Pharmaceutics Ltd

—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026—
—Additional equity investment raises Gilead's ownership stake in Assembly Bio to 29.9%—
–Funding supports pipeline progress, including amendment to accelerate clinical development of Assembly Bio's novel small molecule hepatitis D virus candidate ABI-6250—
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced an equity investment of $20.1 million by Gilead Sciences, Inc. ("Gilead") to purchase additional Assembly Bio common stock and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%.
Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus (HDV) and hepatitis B virus (HBV). Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025.
The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of HDV, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated.

Biotech

Contracts

General

ASMB

GILD

Assembly Biosciences Announces $30.1M Equity Investment And Accelerated Funding From Gilead To Advance Clinical Development Programs; Additional Equity Investment Raises Gilead's Ownership Stake In Assembly Bio To 29.9%

QNRX

Quoin Pharmaceuticals Receives FDA Clearance To Initiate A New QRX003 Netherton Syndrome Clinical Study

Goldman Sachs analyst Mark Delaney maintains Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) with a Buy and raises the price target from $145 to $160.

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Jabil, Raises Price Target to $160

UAVS

AgEagle Aerial Systems Secures Largest Sensor Order In Company History With Milestone Sale Of 60 RedEdge-P Multispectral Sensors To East Asian Reseller, Highlighting 2024 Growth And Focus On Long-Term Shareholder Value

– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier –
– Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery –
– Data support advancement to Phase 2 clinical trial in multiple sclerosis, anticipated in 2H 2025 –
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive data from a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-ascending doses of A-005, a potent, selective, central nervous system (CNS) penetrant TYK2 inhibitor, in healthy participants.

ALMS

Alumis Announces Phase 1 Data For CNS Penetrant TYK2 Inhibitor, A-005; A-005 Was Well Tolerated And Demonstrated Ability To Cross Blood-Brain Barrier

Rosenblatt analyst Kevin Cassidy maintains Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) with a Buy and maintains $27 price target.

Penguin Solutions, Inc. - Ordinary Shares

PENG

Rosenblatt Maintains Buy on Penguin Solutions, Maintains $27 Price Target

Agreement&nbsp;Reached on Primary Endpoint and Phase 3 Trial Design
Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering
FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small-molecule drugs to treat other ophthalmologic disorders, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).
The SPA agreement reflects that the proposed Phase 3 trial design, endpoints, and planned analyses will be adequate to support a New Drug Application (NDA) submission for treatment of NPDR, subject to a successful outcome of the trial and review of all data in the NDA. The agreed primary endpoint is a reduction in 3-step or greater worsening on the binocular diabetic retinopathy severity scale (DRSS) score, compared to placebo. In the previous Phase 2 ZETA-1 trial, oral APX3330 showed the potential to slow or prevent clinically meaningful progression of DR and demonstrated a favorable safety profile.

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Trial Of APX3330 In Diabetic Retinopathy; Agreement Reached On Primary Endpoint And Phase 3 Trial Design

Backed By Data From Transpher A Study Showing Sustained Cognitive Improvements And Mild Adverse Events

RARE

Ultragenyx Submits Biologics License Application To FDA For UX111 AAV Gene Therapy Seeking Accelerated Approval For Sanfilippo Syndrome Type A Treatment

Offerings

GXAI

Gaxos.ai Announces $5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules; Totaling 1.45M Shares At $3.32 Per Share, Closing Expected By Dec. 20, 2024

LDOS

Leidos Secures $987M Contract For F-16 Foreign Military Sales Sustainment, Supporting U.S. Air Force's F-16 System Program Office Over 10 Years

Across the recent three months, 8 analysts have shared their insights on Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Universal Technical and provided 12-month price targets. The average target is $25.5, accompanied by a high estimate of $30.00 and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 17.95% from the previous average price target of $21.62.
<img src="https://www.benzinga.com/files/images/story/2024/1734613298_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Universal Technical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Steve Frankel</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jasper Bibb</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Raj Sharma</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Universal Technical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Universal Technical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Universal Technical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Universal Technical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Universal Technical: A Closer Look</h2>
Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.
<h3>A Deep Dive into Universal Technical's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Universal Technical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 15.3%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Universal Technical's net margin is impressive, surpassing industry averages. With a net margin of 9.59%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Universal Technical's ROA excels beyond industry benchmarks, reaching 2.6%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.13, Universal Technical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Universal Technical Through The Eyes Of 8 Analysts

Rosenblatt analyst Hans Mosesmann maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and maintains $250 price target.

Rosenblatt Maintains Buy on Micron Technology, Maintains $250 Price Target

In the preceding three months, 19 analysts have released ratings for Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Tapestry and provided 12-month price targets. The average target is $62.95, accompanied by a high estimate of $80.00 and a low estimate of $52.00. This current average has increased by 15.63% from the previous average price target of $54.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1734613285_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Tapestry among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Rick Patel</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Hold</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tapestry. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tapestry compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tapestry's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Tapestry's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tapestry analyst ratings.</a>
<h2>All You Need to Know About Tapestry</h2>
Coach, Kate Spade, and Stuart Weitzman are Tapestry's fashion and accessory brands. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (64% of fiscal 2024 sales), Europe, Asia (29% of fiscal 2024 sales), and elsewhere. Coach (76% of fiscal 2024 sales) is best known for affordable luxury leather products. Kate Spade (20% of fiscal 2023 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2024. Stuart Weitzman (4% of sales) generates virtually all its revenue from women's footwear.
<h3>Understanding the Numbers: Tapestry's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Tapestry faced challenges, resulting in a decline of approximately -0.38% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Tapestry's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Tapestry's ROE excels beyond industry benchmarks, reaching 6.35%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tapestry's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.38%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Tapestry's debt-to-equity ratio surpasses industry norms, standing at 2.95. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

19 Analysts Assess Tapestry: What You Need To Know

15 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and a low estimate of $75.00. This current average has decreased by 5.25% from the previous average price target of $167.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1734613269_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Sarepta Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Sell</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$202.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Sell</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sarepta Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Sarepta Therapeutics</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>A Deep Dive into Sarepta Therapeutics's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sarepta Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 40.79%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sarepta Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.19%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE excels beyond industry benchmarks, reaching 2.93%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.96%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.14.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SRPT

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts

Maxim Group analyst Jack Vander Aarde initiates coverage on NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) with a Buy rating and announces Price Target of $12.

Initiation

NIPG

Maxim Group Initiates Coverage On NIP Group with Buy Rating, Announces Price Target of $12

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for IonQ, revealing an average target of $25.0, a high estimate of $50.00, and a low estimate of $13.00. This upward trend is evident, with the current average reflecting a 88.68% increase from the previous average price target of $13.25.
<img src="https://www.benzinga.com/files/images/story/2024/1734613256_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive IonQ is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Platt</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to IonQ. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of IonQ compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of IonQ's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of IonQ's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IONQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IonQ analyst ratings.</a>
<h2>Discovering IonQ: A Closer Look</h2>
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems, and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
<h3>IonQ's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, IonQ showcased positive performance, achieving a revenue growth rate of 102.09% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -423.35%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): IonQ's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -11.68%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): IonQ's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.34%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.04, IonQ adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IONQ

Breaking Down IonQ: 5 Analysts Share Their Views

Analysts' ratings for Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) over the last quarter vary from bullish to bearish, as provided by 40 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">22</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">13</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $99.0, along with a high estimate of $140.00 and a low estimate of $75.00. A 1.27% drop is evident in the current average compared to the previous average price target of $100.27. 
<img src="https://www.benzinga.com/files/images/story/2024/1734613244_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Okta by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$96.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$94.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$96.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$81.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$92.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$97.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Gray Powell</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$98.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Okta. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Okta compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Okta's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Okta's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OKTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Okta analyst ratings.</a>
<h2>About Okta</h2>
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
<h3>Okta's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Okta showcased positive performance, achieving a revenue growth rate of 13.87% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.41%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.18%, the company showcases effective utilization of assets.
Debt Management: Okta's debt-to-equity ratio is below the industry average. With a ratio of 0.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OKTA

Demystifying Okta: Insights From 40 Analyst Reviews

Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares are trading lower in the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Thursday</a>.
The company <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42571377/lamb-weston-reports-second-quarter-fiscal-2025-results-board-approves-250-million-share-repurchase" rel="noreferrer noopener">reported second-quarter</a> adjusted earnings per share of 66 cents, missing the street view of $1.01. Quarterly sales of $1.60 billion (down 8% year-over-year) missed the analyst consensus estimate of $1.674 billion.
Volume dropped by 6 percent in the quarter due to weak global restaurant traffic and customer share losses, partially offset by gains.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42571954/why-is-penny-stock-canoo-falling-on-thursday" rel="noreferrer noopener">Why Is Penny Stock Canoo Falling On Thursday?</a>
The decline also reflects the company's decision last year to exit a lower-priced, lower-margin business in Europe to manage its customer and product mix better.
"Higher-than-expected manufacturing costs and softer volumes accounted for the shortfall, while price/mix and operating expenses were broadly in line with our targets for the quarter," said CEO Tom Werner.
"In terms of the broader operating environment, we expect challenging conditions to persist through the remainder of fiscal 2025 and into fiscal 2026," he added.
Net sales for the North America segment fell 8% to $1.072 billion, while the International segment decreased 6% to $528.8 million.&nbsp;
Adjusted gross profit&nbsp;declined by $134.9 million to $343.5 million versus the prior year quarter due to unfavorable price/mix, higher manufacturing costs per pound, and lower sales volumes.
Adjusted EBITDA declined by $95.0 million to $281.9 million compared to the prior year quarter, primarily due to lower net sales and adjusted gross profit.
As of November 24, the company had $79.0 million of cash and cash equivalents and $1.211 billion of available liquidity under its revolving credit facility.
Dividend Hike: In December 2024, the company approved an increase of $250 million in the company's existing $500 million share repurchase authorization under the program to an aggregate total of $750 million.
In addition, the board declared a quarterly dividend of 37 cents per share of Lamb Weston common stock, an increase of 1 cent.
The dividend is payable on February 28 to stockholders of record as of the close of business on January 31, 2025.
CEO Appointment: Lamb Weston announced the appointment of Michael J. Smith, currently COO, as<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42571401/lamb-weston-announces-appointment-of-michael-j-smith-as-president-and-chief-executive-officer" rel="noreferrer noopener"> President and CEO, effective January 3, 2025</a>. He will also join the company's Board of Directors.
Smith succeeds Thomas P. Werner, who is stepping down but will serve in an advisory role until August 31, 2025.
Outlook: Lamb Weston has lowered its FY25 outlook, now expecting net sales of $6.35 billion to $6.45 billion, down from a prior outlook of $6.6 billion-$6.8 billion. The analyst consensus estimate pegs at $6.65 billion.
The company also revised its adjusted EPS projection to $3.05-$3.20, below the previous outlook of $4.15-$4.35. The street view stands at $4.20.
Price Action: LW shares are trading lower by 20.80% to $61.97&nbsp;premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42569883/quantum-computing-rigetti-d-wave-skyrocket-up-to-300-in-5-sessions-after-google-unveils-willow-chip-but-analysts-urge-caution-not-every-tiktok-guitarist-is-the-next-taylor-swift" target="_blank" rel="noreferrer noopener">Quantum Computing, Rigetti, D-Wave Skyrocket Up To 300% In 5 Sessions After Google Unveils Willow Chip, But Analysts Urge Caution: ‘Not Every TikTok Guitarist Is The Next Taylor Swift'</a></li>
</ul>
Photo Courtesy of Lamb Weston

Earnings

Equities

Guidance

Lamb Weston Takes A Hit From High Manufacturing Costs And Softer Volumes, Expects Challenging Conditions Till 2026

Market-Moving Exclusives

Exclusives

VANI

EXCLUSIVE: Vivani Medical Tells Benzinga 'Study represents the first clinical application of NanoPortal, the Company's proprietary drug implant platform technology'

On Thursday, Vivani Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) initiated screening and enrollment at two centers in Australia for the first-in-human clinical trial, LIBERATE-1.
The trial investigates the safety, tolerability, and full pharmacokinetic profile of an exenatide implant.
Vivani&#8217;s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40704367/exclusive-vivani-medical-reveals-positive-preclinical-liver-fat-results-from-miniature-glp-1-impl" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity</a>
The study is the first clinical application of the company&#8217;s proprietary NanoPortal drug implant technology.
In September, the Bellberry Human Research Ethics Committee approved, and the Therapeutic Goods Administration in Australia formally acknowledged a first-in-human clinical trial of the company&#8217;s miniature, subdermal GLP-1 (exenatide) implant in obese and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41044242/exclusive-vivani-medical-advances-its-obesity-treatment-implant-with-new-clinical-trial-in-austra" rel="noreferrer noopener">overweight subjects</a>.
The trial will enroll participants who will be titrated on weekly semaglutide injections for 8 weeks before being randomized to receive a single administration of Vivani&#8217;s exenatide implant (n=8), weekly exenatide injections (n=8), or weekly 1 mg semaglutide injections (n=8) for 9-week treatment duration.
Weight changes will be measured. The company anticipates that top-line data will be available in mid-2025.
If available, Vivani intends to utilize research and development incentives and rebates from the Australian government to defray some of the costs from this clinical trial.
Since clinical studies conducted in Australia comply with the International Conference on Harmonization guidelines, data generated in Australia are generally acceptable to the FDA and other regulatory authorities.
Vivani anticipates using relevant clinical data generated in Australia to support regulatory submissions in other geographies, including the U.S.
Vivani&#8217;s pipeline also includes NPM-139 (semaglutide implant), which is also under development for chronic weight management in obese and overweight individuals.
Price Action: VANI stock is up 0.83% at $1.22 during the premarket session at last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a></li>
</ul>

Health Care

EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia

NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics is advancing its preclinical program centered on dual orexin receptor agonists (...

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment

NLS Pharmaceutics (NLSP) shared preclinical data demonstrating the potential of its dual orexin receptor agonist platform. AEX-41 and AEX-2, two fi...

NLS Pharmaceutics announces preclinical data on DOXA platform

NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics has released promising preclinical data for its innovative dual orexin receptor ...

NLS Pharmaceutics Unveils Promising Data for New Treatments

NLS Pharmaceutics announces pricing of private placement of up to $1M

NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics Ltd., a Swiss company, has entered into a Securities Purchase Agreement that all...

NLS Pharmaceutics Offers New Investment Opportunities

Which subsectors to own and which to avoid – Wolfe Research

NLS Pharmaceutics (NLSP) announced that its CEO Alex Zwyer, has issued a letter to shareholders, which read in part, "Over the past several months,...

NLS Pharmaceutics expects to close Kadimastem merger by end of January

NLS Pharmaceutics ( ($NLSP) ) just unveiled an update. NLS Pharmaceutics announced substantial progress in its Dual Orexin Receptor Agonist (DOXA) ...

NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans

NLS Pharmaceutics ( ($NLSP) ) has issued an update. NLS Pharmaceutics, a company based in Zurich, Switzerland, has scheduled an extraordinary share...

NLS Pharmaceutics Plans Capital Increase at Extraordinary Shareholders' Meeting

AAPL

AMZN

BILI

BRCC

CRDO

DBAW

DFAX

ESPO

FTXG

GLBE

GOOGL

IBUY

KBWB

MAGS

MATV

MSFT

NVDA

ONLN

PRFX

QUAL

REPYY

RGTI

SCHG

SDVY

SMOT

SOCL

SOXX

SPYG

SPYV

SUPV

TRAW

TROX

TSLA

TZOO

WEST

Press Releases

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and  Expected Compliance with Nasdaq Continued Listing Rules

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Peraso Inc. (NASDAQ: PRSO) Volume Soars as SAF Tehnika Adopts Technology Across a $3.4B Market North America & Europe – More Stocks Inside!

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

ATLN

NLSPW

PRSO

Laidlaw & Co.

Comments

NLS Pharmaceutics

NLS Pharmaceutics (NLSP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga